HK Stock Market Move | CARSGEN-B (02171) fell by over 10%, the world's first solid tumor CAR-T treatment costs 990,000 per injection, with only an estimated 200 orders expected to be received this year.

CARSGEN-B (02171) fell by over 10%, as of the time of publication, it fell by 10.21% to 12.49 Hong Kong dollars, with a trading volume of 94.7869 million Hong Kong dollars. On the news front, recently, Koji Pharmaceutical announced that its self-developed Claudin18.2 autologous humanized CAR-T cell therapy product, Kailimei (Shurui Ji'aolan Sai Injection), has received approval from the National Medical Products Administration for a new drug listing application. The official price of Kailimei is set at 990,000 yuan per person, taking into account the pricing of other CAR-T products on the market, epidemiology, and payment factors. Senior officials of Koji Pharmaceutical stated that the initial target patient group for Shurui Ji'aolan Sai is mainly high-net-worth individuals with strong payment capabilities. Koji Pharmaceutical has made preliminary sales volume expectations for the future, estimating that Shurui Ji'aolan Sai will only receive 200 orders by 2026, and predicting that it will take 4-5 years after its launch to reach a sales peak of around 2 billion yuan.